Skip to content

Study · Animal study (in vivo) · rat · 2017

4 results

JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.

Bresciani E, Rizzi L, Molteni L, Ravelli M, Liantonio A, Ben Haj Salah K, Fehrentz JA, Martinez J, Omeljaniuk RJ, Biagini G, Locatelli V, Torsello A

Endocrine28 Nov 2016Cited by 13 (Europe PMC)

PMID27896546 (opens in a new tab)DOI10.1007/s12020-016-1184-2 (opens in a new tab)PepBankPUB-27896546
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In neonatal rats, hexarelin behaved as a full agonist of the growth hormone secretagogue receptor by stimulating growth hormone release.

    In plain wordsIn neonatal rats, hexarelin stimulated release of growth hormone.

    Peptide
    Hexarelin
    Outcome
    IncreaseGrowth hormone release in neonatal rats
    Study

    ratn: not reported in source

    Neonatal rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The three growth hormone secretagogues behaved as full agonists of the growth hormone secretagogues receptor both in terms of ability to stimulate calcium mobilization in Chinese hamster ovary cells and stimulation of growth hormone release in neonatal rats.
    1 context sentence
    Summary · context
    The purpose of this study was to investigate whether selected growth hormone secretagogues including hexarelin, JMV2894 and JMV2951 could antagonize body weight loss and wasting induced by cisplatin administration in rats.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In cisplatin-treated rats, hexarelin caused an initial transient acute increase in food intake.

    In plain wordsIn rats given cisplatin, hexarelin caused a short rise in food intake at the start.

    Peptide
    Hexarelin
    Outcome
    IncreaseAcute food intake
    Study

    ratn: not reported in source

    Cisplatin-treated adult rats
    Comparator
    Vehicle
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 12 daysAs given in this study (rat).

    Source sentences

    Summary
    Although all growth hormone secretagogues caused initial transient acute increases in food intake, the total amount of food eaten by controls and growth hormone secretagogues treated groups over the 12 experimental days was not significantly different.
    1 context sentence
    Summary · context
    Adult rats were (i) treated with vehicle throughout (controls), or (ii) treated with cisplatin (days 1-3) and a growth hormone secretagogues or vehicle, (days 1-12).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, total food eaten over the 12 experimental days did not differ significantly between controls and hexarelin-treated groups.

    In plain wordsIn rats, total food eaten over 12 days was not clearly different between hexarelin-treated groups and controls.

    Peptide
    Hexarelin
    Outcome
    No significant changeTotal food intake over 12 days
    Study

    ratn: not reported in source

    Cisplatin-treated adult rats
    Comparator
    Vehicle controls
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · 12 daysAs given in this study (rat).

    Source sentences

    Summary
    Although all growth hormone secretagogues caused initial transient acute increases in food intake, the total amount of food eaten by controls and growth hormone secretagogues treated groups over the 12 experimental days was not significantly different.
    1 context sentence
    Summary · context
    Adult rats were (i) treated with vehicle throughout (controls), or (ii) treated with cisplatin (days 1-3) and a growth hormone secretagogues or vehicle, (days 1-12).
  4. 04LabIn vitro (cells)Activity measurement

    In Chinese hamster ovary cells, hexarelin behaved as a full agonist of the growth hormone secretagogue receptor in calcium mobilization.

    In plain wordsIn cells, hexarelin fully activated the growth hormone secretagogue receptor, measured by calcium release.

    Peptide
    Hexarelin
    Outcome
    Not applicableCalcium mobilization in CHO cells (GHSR agonism)
    Study

    hamstern: not reported in source

    Chinese hamster ovary cells
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The three growth hormone secretagogues behaved as full agonists of the growth hormone secretagogues receptor both in terms of ability to stimulate calcium mobilization in Chinese hamster ovary cells
    1 context sentence
    Summary · context
    The purpose of this study was to investigate whether selected growth hormone secretagogues including hexarelin, JMV2894 and JMV2951 could antagonize body weight loss and wasting induced by cisplatin administration in rats.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.